Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
First Hawaiian
FHB
$3.2B
| $16.5M | 0.02% |
563,704
+553,469
| +5,408% | +$15.1M |
|
777
West Pharmaceutical
WST
$24.8B
| $16.4M | 0.02% |
45,766
+44,645
| +3,983% | +$13.6M |
|
778
Warrior Met Coal
HCC
$5.64B
| $16.4M | 0.02% |
202,254
+79,172
| +64% | +$7.16M |
|
779
PUT
Applovin
APP
$102B
| $16.4M | 0.02% |
31,800
+4,600
| +17% | +$2.22M |
|
780
Fidelity National Financial
FNF
$12.7B
| $16.4M | 0.02% |
+347,090
| New | +$16.8M |
|
781
CALL
Honeywell
HON
$68.4B
| $16.4M | 0.02% |
73,100
+66,000
| +930% | +$14.7M |
|
782
Southwest Gas
SWX
$6.44B
| $16.2M | 0.02% |
182,979
-382,937
| -68% | -$34.3M |
|
783
Dover
DOV
$27.2B
| $16.2M | 0.02% |
72,232
-176,351
| -71% | -$38.4M |
|
784
Annexon
ANNX
$961M
| $16.2M | 0.02% |
2,830,976
-1,055,933
| -27% | -$5.84M |
|
785
Scotiabank
BNS
$107B
| $16.1M | 0.02% |
+185,700
| New | +$14.6M |
|
786
Vera Therapeutics
VERA
$2.33B
| $16.1M | 0.02% |
374,951
-44,619
| -11% | -$1.66M |
|
787
CALL
Alphabet (Google) Class A
GOOGL
$4.22T
| $16.1M | 0.02% |
45,000
-43,000
| -49% | -$15.5M |
|
788
Rush Street Interactive
RSI
$2.98B
| $16.1M | 0.02% |
539,774
-368,097
| -41% | -$9.7M |
|
|
DX
789
Dynex Capital
DX
$3.23B
| $16M | 0.02% |
1,220,139
-1,219,509
| -50% | -$16M |
|
790
PUT
Occidental Petroleum
OXY
$61.3B
| $16M | 0.02% |
328,800
+31,900
| +11% | +$1.81M |
|
791
Tidewater
TDW
$4.74B
| $16M | 0.02% |
239,673
+82,827
| +53% | +$6.57M |
|
792
Avalo Therapeutics
AVTX
$1.06B
| $15.9M | 0.02% |
861,711
+130,125
| +18% | +$2.06M |
|
793
Dianthus Therapeutics
DNTH
$6.21B
| $15.8M | 0.02% |
162,005
-312,080
| -66% | -$27.3M |
|
794
Trevi Therapeutics
TRVI
$2.56B
| $15.8M | 0.02% |
845,087
+371,238
| +78% | +$5.4M |
|
795
Marathon Digital Holdings
MARA
$4.35B
| $15.8M | 0.02% |
1,134,250
+902,850
| +390% | +$11.3M |
|
796
Nexstar Media Group
NXST
$5.73B
| $15.7M | 0.02% |
88,190
-170,585
| -66% | -$31.9M |
|
|
BOBS
797
Bobs Discount Furniture
BOBS
$2.29B
| $15.7M | 0.02% |
991,160
-333,726
| -25% | -$4.14M |
|
798
CALL
Astera Labs
ALAB
$49.4B
| $15.6M | 0.02% |
32,400
+22,600
| +231% | +$6M |
|
799
First Watch Restaurant Group
FWRG
$804M
| $15.6M | 0.02% |
1,211,627
+930,650
| +331% | +$10.9M |
|
800
CME Group
CME
$98.9B
| $15.6M | 0.02% |
70,710
-393,914
| -85% | -$109M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.